Skip to main content

Table 4 SIR of site-specific cancer of the HIV-infection patients group in different gender and overall population

From: Risk of cancer among HIV-infected patients from a population-based nested case–control study: implications for cancer prevention

  Men Women All
  Cases of cancer Cases of cancer Cases of cancer
Cancer site Observed Expected SIR (95% CI) Observed Expected SIR (95% CI) Observed Expected SIR (95% CI)
ENT (140–149) 10 4 3.15*** (1.38 ~ 7.20) 1 <0.5 N/A 11 4 2.77*** (1.28 ~ 5.98))
 Oral (140–146) 8 2.75 4.09*** (1.53 ~ 10.93) 1 <0.5 N/A 9 2.75 3.29*** (1.36 ~ 7.96)
 Non- Oral (147–149) 2 2.25 0.85 (0.27 ~ 6.72) <0.5 <0.5 N/A 2 2.25 0.89 (0.19 ~ 4.12)
GI (150 ~ 159) 20 7 2.99*** (1.69 ~ 5.27) 10 5 1.96 (0.77 ~ 3.41) 30 12 2.54*** (1.60 ~ 4.06)
 Liver (155) 11 3 3.76*** (1.65 ~ 8.55) 2 1.5 1.15 (0.35 ~ 2.43) 13 4.5 3.75*** (1.76 ~ 7.99)
 Colorectal (153–154) 7 2.5 2.59* (1.06 ~ 6.72) 4 2.5 1.52 (0.48 ~ 4.82) 11 5 2.21* (1.06 ~ 4.63)
 Others (150–152,156-159) 5 1.75 2.91*** (1.92 ~ 9.19) 3 2.25 1.36 (0.75 ~ 3.01) 8 4 2.01 (0.86 ~ 4.70)
 Anus (154.2-154.8) <0.5 <0.5 N/A 1 <0.5 N/A 1 <0.5 N/A
 Stomach (151) 2 0.75 2.71 (0.45 ~ 16.24) 1 <0.5 N/A 3 1 3.07 (0.69 ~ 13.73)
Respiratory & intrathoracic (160–165) 12 3.25 3.28*** (1.53 ~ 7.03) 4 1 4.53*** (1.21 ~ 14.69) 16 3.75 4.31*** (2.13 ~ 8.75)
 Lung (162) 9 3.25 2.83*** (1.21 ~ 6.64) 4 0.5 6.13*** (1.87 ~ 28.69) 13 3.75 3.49*** (1.66 ~ 7.37)
 Non Lung (160–161, 163–165) 4 <0.5 N/A 1 <0.5 N/A 5 <0.5 N/A
Bone,connective tissue (170–176) 15 <0.5 N/A 7 2.75 3.26*** (1.59 ~ 11.46) 22 3 7.46*** (3.68 ~ 15.12)
 Breast (174–175) 1 <0.5 N/A 4 1.25 2.80*** (1.29 ~ 10.01) 5 1.25 4.01* (1.16 ~ 13.89)
 Skin & soft tissue (170–173) 2 <0.5 N/A- 4 1.5 8.44*** (1.54 ~ 46.32) 6 1.75 3.44* (1.15 ~ 10.26)
 Malignant melanoma of skin (172) <0.5 <0.5 N/A <0.5 <0.5 N/A <0.5 <0.5 N/A
 Other skin & soft tissue (170, 171, 173) 2 <0.5 N/A 4 1.5 8.44*** (1.54 ~ 46.32) 6 1.75 3.44* (1.15 ~ 10.26)
 Kaposi (176) 12 <0.5 N/A <0.5 <0.5 N/A 12 <0.5 N/A
 Bone (170) <0.5 <0.5 N/A <0.5 <0.5 N/A <0.5 <0.5 N/A
GU (180–189) 7 2.5 2.57*** (1.29 ~ 9.88) 9 3 3.71*** (1.84 ~ 12.59) 16 5.5 2.94*** (1.54 ~ 5.61)
 Kidney & bladder (188–189) 4 0.5 8.15*** (1.49 ~ 44.58) 2 0.75 2.15 (0.87 ~ 8.65) 6 1.25 4.82*** (1.47 ~ 15.83)
 Cervical (180) <0.5 <0.5 N/A 4 1 4.01* (1.0 ~ 16.06) 4 1 4.01* (1.0 ~ 16.06)
 Others (179,181-187) 4 1.25 2.71 (0.76 ~ 9.64) 5 2.5 2.75*** (1.21 ~ 6.25) 9 3.75 2.41* (1.05 ~ 5.53)
Lymphoma (200–203) 12 0.75 12.22*** (3.08 ~ 36.12) 3 0.89 3.38(0.63 ~ 8.28) 15 0.75 20.26*** (5.86 ~ 70.10)
 Non Hodgkin lymphoma (200, 202.0-202.2, 202.8-202.9) 10 0.5 21.65*** (5.65 ~ 88.75) 3 0.77 3.90(0.73 ~ 9.55) 13 0.5 25.73*** (6.83 ~ 90.85)
Leukemia (204–208) 1 1 1.00 (0.10 ~ 8.96) <0.5 <0.5 N/A 1 1 1.00 (0.10 ~ 8.96)
CNS (190–192) 2 <0.5 N/A 3 <0.5 N/A 5 <0.5 N/A
Thyroid (193) <0.5 <0.5 N/A 2 <0.5 N/A 2 1 2.01 (0.37 ~ 10.94)
Others (194–199) 6 4 2.05 (0.76 ~ 3.99) 6 3.25 1.76 (0.89 ~ 6.16) 12 7.25 1.66 (0.85 ~ 3.37)
  1. SIR: standardized incidence ratios.
  2. ENT: ear-nasal cavity-throat.
  3. CNS: central nervous system.
  4. GI: gastroenteral.
  5. GU: genitouro.
  6. *P < 0.05, ***P < 0.001.
  7. N/A: no calculation of SIR due to case number or expected number less than 0.5.
\